7 results
6-K
EX-99.1
SNY
Sanofi
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
From Leaders to Citizens
Q1 2023
Q2 2023
KPI
65% of the leaders have completed the eLearning phase
9% of the leaders have completed the full program
6-K
EX-99.1
SNY
Sanofi
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
with communities
Q4 2022
Q1 2023
# volunteers
4,975 volunteers
Next update in Q2 2023
# hours
26,906 hours
From Leaders to Citizens
Q4 2022
Q1 2023
KPI
6-K
EX-99.1
SNY
Sanofi
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
2022
Q3 2022
# volunteers
1,998 volunteers
3,498 volunteers
# hours
12,687 hours
25,265 hours
From Leaders to Citizens
Q2 2022
Q3 2022
KPI
Roll out
6-K
EX-99.1
SNY
Sanofi
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
Leaders to Citizens
Q1 2021
Q2 2022
KPI
Roll out planned in 2022
ESG ratings
The continuous implementation of Sanofi’s social impact strategy has led
6-K
EX-99.2
SNY
Sanofi
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
2022
# volunteers
4,975 volunteers
1,998 volunteers
# hours
26,906 hours
12,687 hours
From Leaders to Citizens
Q1 2022
Q2 2022
KPI
Roll out planned
6-K
EX-99.1
9ndzcrk mfs4aksdt6
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.1
3f4zh
4 Feb 22
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D
9:56am
- Prev
- 1
- Next